Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Lijun Zhang et al.|The Lancet|2014Cited by 4.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, David Cameron, Gerold Meinhardt et al.|New England Journal of Medicine|2022Cited by 2.5k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Martine Piccart, Marion Procter et al.|The Lancet|2007Cited by 1.5k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Harold J. Burstein, Binghe Xu, Giuseppe Curigliano et al.|Annals of Oncology|2021Cited by 799
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Joseph Gligorov et al.|Annals of Oncology|2021Cited by 724